Home > Insider Trading > Filing (0001628280-21-025683)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
727207	Accelerate Diagnostics Inc	AXDX	Laboratory Analytical Instruments (3826)	841072256

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1021412	W Jack Schuler	C/O Accelerate Diagnostics, Inc. 3950 S. Country Club Road, Suite 470 Tucson AZ 85714		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-12-28	30,000	$4.87	18,480,631	No	4	P	Indirect	By Jack W. Schuler Living Trust
Common Stock	Acquisiton	2021-12-29	27,062	$4.83	18,507,693	No	4	P	Indirect	By Jack W. Schuler Living Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Jack W. Schuler Living Trust
No	4	P	Indirect	By Jack W. Schuler Living Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	54,975	Indirect	By Spouse

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.79 to $4.96, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.90, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.